(Q30373734)

17 August 2017

Meeting report: risk assessment of tamiflu use under pandemic conditions. (English)

1 reference

17 August 2017

0 references

1 reference

Matthew Sanders

34

0 references

Maria Ludovica Saccà

Maria Ludovica Saccà

33

0 references

Cesare Accinelli

Cesare Accinelli

6

0 references

Michael J Dempsey

Michael J Dempsey

18

0 references

Jürg Oliver Straub

Jürg Oliver Straub

35

0 references

Anna Barra Caracciolo

Anna Barra Caracciolo

7

0 references

Elise Cartmell

Elise Cartmell

13

0 references

Andrew C Johnson

Andrew C Johnson

3

0 references

Andrew Singer

Andrew C Singer

1

0 references

Tom Hutchinson

Tom Hutchinson

23

0 references

Nikolaos Voulvoulis

Nikolaos Voulvoulis

40

0 references

John Oxford

29

John Oxford

1 reference

17 August 2017

17

Mark Crane

1 reference

17 August 2017

28

Miles A Nunn

1 reference

17 August 2017

11

Alistair Boxall

1 reference

17 August 2017

Bruce M Howard

2

1 reference

17 August 2017

Chris J Knowles

4

1 reference

17 August 2017

Simon Jackman

5

1 reference

17 August 2017

Ian Bernard

8

1 reference

17 August 2017

Stephen Bird

9

1 reference

17 August 2017

Tatiana Boucard

10

1 reference

17 August 2017

Jayne V Brian

12

1 reference

17 August 2017

Chris Chubb

14

1 reference

17 August 2017

John Churchley

15

1 reference

17 August 2017

Sandra Costigan

16

1 reference

17 August 2017

Bob Dorrington

19

1 reference

17 August 2017

Brian Ellor

20

1 reference

17 August 2017

Jerker Fick

21

1 reference

17 August 2017

John Holmes

22

1 reference

17 August 2017

Franz Karcher

24

1 reference

17 August 2017

Samuel L Kelleher

25

1 reference

17 August 2017

Peter Marsden

26

1 reference

17 August 2017

Gerald Noone

27

1 reference

17 August 2017

Tony Rachwal

30

1 reference

17 August 2017

Noel Roberts

31

1 reference

17 August 2017

Mike Roberts

32

1 reference

17 August 2017

Adrian Terry

36

1 reference

17 August 2017

Dean Thomas

37

1 reference

17 August 2017

Stephen Toovey

38

1 reference

17 August 2017

Rodney Townsend

39

1 reference

17 August 2017

Chris Watts

41

1 reference

17 August 2017

30 May 2008

1 reference

Environmental Health Perspectives

17 August 2017

5

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

17 August 2017

116

1 reference

17 August 2017

11

1 reference

17 August 2017

1563-1567

1 reference

Progress and shortcomings in European national strategic plans for pandemic influenza

17 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592279

Influenza virus susceptibility and resistance to oseltamivir.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592279

Antiviral oseltamivir is not removed or degraded in normal sewage water treatment: implications for development of resistance by influenza A virus

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592279

Potential risks associated with the proposed widespread use of Tamiflu.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592279

Antiviral resistance and the control of pandemic influenza

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592279

Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592279

Bacterial neuraminidase facilitates mucosal infection by participating in biofilm production

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592279

Antivirals for influenza: historical perspectives and lessons learned

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592279

Strategies for mitigating an influenza pandemic

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592279

Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592279

Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592279

Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592279

Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592279

Treatment of influenza with neuraminidase inhibitors: virological implications

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592279

Oral oseltamivir treatment of influenza in children.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592279

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592279

News about influenza B drug resistance that cannot be ignored

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592279

H5N1 Oseltamivir-resistance detection by real-time PCR using two high sensitivity labeled TaqMan probes

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592279

Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592279

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592279

26 November 2018

Identifiers

DOI

10.1289/EHP.11310

1 reference

17 August 2017

1 reference

17 August 2017

PubMed publication ID

19057712

1 reference